News
In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...
Investors soured on the sector when Elevance, an insurer, handed in disappointing results and shared a downbeat outlook.
Our Top 5 Analyst Questions Eli Lilly’s Q1 Earnings Call Asad Haider (Goldman Sachs) asked about the impact of the CVS formulary loss on Zepbound’s market share and future PBM dynamics.
Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent ...
8h
Zacks Investment Research on MSNEli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.
Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...
J&J (NYSE:JNJ) stock surges rallying peers despite Trump's latest tariff threats on pharma as the company posts a quarterly ...
2d
MarketBeat on MSNGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 OutlookDetailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
In the second quarter, J&J’s worldwide oncology sales shot up more than 20 per cent, offsetting declines in sales of its ...
Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing unique challenges, impacting the ETF’s overall ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results